<DOC>
	<DOCNO>NCT01324336</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetics routinely use compound liquid formulation 6-mercaptopurine ( 6-MP ) commercially available tablet patient receive treatment 6-MP part clinical treatment acute lymphoblastic leukemia ( ALL ) .</brief_summary>
	<brief_title>Comparative Pharmacokinetics Compounded 6-mercaptopurine Liquid Formulation Preparation Tablets</brief_title>
	<detailed_description />
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<criteria>Patients age 417 year age receive maintenance chemotherapy treatment ALL 6MP include . Inability blood drawn screen lab test Received methotrexate folate supplement within last 24 hour Pregnant lactate female Inability swallow pill Hemoglobin le equal 8 gm/dl Presence significant comorbid illness make child ineligible deem investigator Weight &lt; = 16 kg</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>ALL</keyword>
	<keyword>acute lymphoblastic leukemia</keyword>
	<keyword>6-Mercaptopurine</keyword>
	<keyword>Pediatric</keyword>
</DOC>